NIAGARA
08 Dec 2020
Trial Summary
A phase III, randomised, opem-label, multi-center, global study to determine the efficacy and safety of durvalumab alone for adjuvant treatment in patients with muscle-invasive bladder cancer
Acronym:
NIAGARA
ACTRN/NCT /ethics:
NCT03732677
Scientific title:
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
Sponsor / Cooperative group:
AstraZeneca
Trial & Patient Characteristics
| Cancer Type | Bladder |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | Both |
| Tumour Stream | muscle-invasive bladder cancer |
| Cancer Stage | All stages |
| Anticipated Start Date | 2018-11-16 |
| Anticipated End Date | 2025-12-18 |
Participating Hospitals
| Hospitalt | Lyell McEwin Hospital |
|---|---|
| Clinical Trial Coordinator | Andy Phay |
| andy.phay@sa.gov.au | |
| Phone | 08 8282 0833 |
| Principal Investigator | Dr Christopher Hocking |
| Recruitment Status | Recruiting |